GABAA Receptor Agonists
Journal of Medicinal Chemistry, 2008, Vol. 51, No. 15 4447
ioral actions of alcohol. Alcohol.: Clin. Exp. Res. 2005, 29, 1390–
401.
(43) Hartvig, L.; Lukensmejer, B.; Liljefors, T.; Dekermendjian, K. Two
conserved arginines in the extracellular N-terminal domain of the
GABA(A) receptor alpha(5) subunit are crucial for receptor function.
J. Neurochem. 2000, 75, 1746–1753.
(25) Albaugh, P. A.; Marshall, L.; Gregory, J.; White, G.; Hutchison, A.;
Ross, P. C.; Gallagher, D. W.; Tallman, J. F.; Crago, M.; Cassella,
J. V. Synthesis and biological evaluation of 7,8,9,10-tetrahydroimi-
dazo[1,2-c]pyrido[3,4-e]pyrimdin-5(6H)-ones as functionally selective
ligands of the benzodiazepine receptor site on the GABA(A) receptor.
J. Med. Chem. 2002, 45, 5043–5051.
(26) Collins, I.; Moyes, C.; Davey, W. B.; Rowley, M.; Bromidge, F. A.;
Quirk, K.; Atack, J. R.; McKernan, R. M.; Thompson, S. A.; Wafford,
K.; Dawson, G. R.; Pike, A.; Sohal, B.; Tsou, N. N.; Ball, R. G.;
Castro, J. L. 3-Heteroaryl-2-pyridones: benzodiazepine site ligands
with functional delectivity for alpha 2/alpha 3-subtypes of human
GABA(A) receptor-ion channels. J. Med. Chem. 2002, 45, 1887–1900.
(27) Mitchinson, A.; Atack, J. R.; Blurton, P.; Carling, R. W.; Castro, J. L.;
Curley, K. S.; Russell, M. G.; Marshall, G.; McKernan, R. M.; Moore,
K. W.; Narquizian, R.; Smith, A.; Street, L. J.; Thompson, S. A.;
Wafford, K. 2,5-Dihydropyrazolo[4,3-c]pyridin-3-ones: functionally
selective benzodiazepine binding site ligands on the GABAA receptor.
Bioorg. Med. Chem. Lett. 2004, 14, 3441–4.
(28) Yasumatsu, H.; Morimoto, Y.; Yamamoto, Y.; Takehara, S.; Fukuda,
T.; Nakao, T.; Setoguchi, M. The pharmacological properties of
Y-23684, a benzodiazepine receptor partial agonist. Br. J. Pharmacol.
1994, 111, 1170–8.
(29) Haefely, W.; Martin, J. R.; Schoch, P. Novel anxiolytics that act as
partial agonists at benzodiazepine receptors. Trends Pharmacol. Sci.
1990, 11, 452–6.
(30) Grunwald, C.; Rundfeldt, C.; Lankau, H. J.; Arnold, T.; Hofgen, N.;
Dost, R.; Egerland, U.; Hofmann, H. J.; Unverferth, K. Synthesis,
pharmacology, and structure-activity relationships of novel imida-
zolones and pyrrolones as modulators of GABAA receptors. J. Med.
Chem. 2006, 49, 1855–1866.
(31) Krogsgaard-Larsen, P.; Frolund, B.; Jorgensen, F. S.; Schousboe, A.
GABAA receptor agonists, partial agonists, and antagonists. Design
and therapeutic prospects. J. Med. Chem. 1994, 37, 2489–2505.
(32) Rabe, H.; Picard, R.; Uusi-Oukari, M.; Hevers, W.; Lu¨ddens, H.; Korpi,
E. R. Coupling between agonist and chloride ionophore sites of the
GABA(A) receptor: agonist/antagonist efficacy of 4-PIOL. Eur.
J. Pharmacol. 2000, 409, 233–242.
(44) Westh-Hansen, S. E.; Witt, M. R.; Dekermendjian, K.; Liljefors,
T.; Rasmussen, P. B.; Nielsen, M. Arginine residue 120 of the
human GABAA receptor alpha 1, subunit is essential for GABA
binding and chloride ion current gating. Neuroreport 1999, 10, 2417–
2421.
(45) Smith, G. B.; Olsen, R. W. Identification of a [3H]muscimol photo-
affinity substrate in the bovine gamma-aminobutyric acidA receptor
alpha subunit. J. Biol. Chem. 1994, 269, 20380–20387.
(46) Holden, J. H.; Czajkowski, C. Different residues in the GABAA
receptor alpha 1T60-alpha 1K70 region mediate GABA and SR-95531
actions. J. Biol. Chem. 2002, 277, 18785–18792.
(47) Boileau, A. J.; Evers, A. R.; Davis, A. F.; Czajkowski, C. Mapping
the agonist binding site of the GABAA receptor: evidence for a beta-
strand. J. Neurosci. 1999, 19, 4847–4854.
(48) Kloda, J. H.; Czajkowski, C. Agonist-, antagonist-, and benzodiazepine-
induced structural changes in the alpha1 Met113-Leu132 region of
the GABAA receptor. Mol. Pharmacol. 2007, 71, 483–493.
(49) Celie, P. H.; van Rossum-Fikkert, S. E.; van Dijk, W. J.; Brejc, K.;
Smit, A. B.; Sixma, T. K. Nicotine and carbamylcholine binding to
nicotinic acetylcholine receptors as studied in AChBP crystal struc-
tures. Neuron 2004, 41, 907–914.
(50) Aranda, G.; Dessolin, M.; Golfier, M.; Guillerez, M. G. 13C NMR
Study of some Derivatives of 1,3,4-Oxadiazoles, 1,3,4-Thiadiazoles
and Isosydnones. Org. Magn. Res. 1982, 18, 159–164.
(51) Roberts, D. D.; Lewis, S. D.; Ballou, D. P.; Olson, S. T.; Shafer, J. A.
Reactivity of small thiolate anions and cysteine-25 in papain towards
methylmethanethiosulfonate. Biochemistry 1986, 25, 5595–5601.
(52) Horenstein, J.; Akabas, M. H. Location of a high affinity Zn2+ binding
site in the channel of alpha1beta1 gamma-aminobutyric acid A
receptors. Mol. Pharmacol. 1998, 53, 870–877.
(53) Baumann, S. W.; Baur, R.; Sigel, E. Subunit arrangement of gamma-
aminobutyric acid type A receptors. J. Biol. Chem. 2001, 276, 36275–
36280.
(54) Frolund, B.; Tagmose, L.; Liljefors, T.; Stensbol, T. B.; Engblom,
C.; Kristiansen, U.; Krogsgaard-Larsen, P. A novel class of potent
3-isoxazolol GABA(A) antagonists: design, synthesis, and pharmacol-
ogy. J. Med. Chem. 2000, 43, 4930–4833.
(55) Krogsgaard-Larsen, P.; Mikkelsen, H.; Jacobsen, P.; Falch, E.; Curtis,
D. R.; Peet, M. J.; Leah, J. D. 4,5,6,7-Tetrahydroisothiazolo[5,4-
c]pyridin-3-ol and related analogues of THIP. Synthesis and biological
activity. J. Med. Chem. 1983, 26, 895–900.
(56) Brejc, K.; van Dijk, W. J.; Smit, A. B.; Sixma, T. K. The 2.7 A
structure of AChBP, homologue of the ligand-binding domain of the
nicotinic acetylcholine receptor. NoVartis Found. Symp. 2002, 245,
22–29, discussion 29-32, 165-168.
(57) Cromer, B. A.; Morton, C. J.; Parker, M. W. Anxiety over GABA(A)
receptor structure relieved by AChBP. Trends Biochem. Sci. 2002,
27, 280–7.
(58) Brejc, K.; van Dijk, W. J.; Klaassen, R. V.; Schuurmans, M.; van Der
Oost, J.; Smit, A. B.; Sixma, T. K. Crystal structure of an ACh-binding
protein reveals the ligand-binding domain of nicotinic receptors. Nature
2001, 411, 269–276.
(59) Wagner, D. A.; Czajkowski, C. Structure and dynamics of the GABA
binding pocket: A narrowing cleft that constricts during activation.
J. Neurosci. 2001, 21, 67–74.
(60) Jin, R.; Banke, T. G.; Mayer, M. L.; Traynelis, S. F.; Gouaux, E.
Structural basis for partial agonist action at ionotropic glutamate
receptors. Nat. Neurosci. 2003, 6, 803–810.
(61) Aboul-Enein, M. N.; Azzouny, A. A.; Abdallah, N. A.; El-Shabrawy
Makhlouf, A. A.; Werner, W. Synthesis of Certain 5-Piperidyl-
1,3,4-Oxadiazol-2(3H)-ones and -2(3H)-thiones having Nonulcero-
genic, Antiinflammatory and Analgesic Activities. Sci. Pharm. 1995,
63, 175–190.
(62) Bentley, K. W.; Burton, M.; Uff, B. C. 1,3,4-Oxadiazol-2(3H)-one
Formation from N-Acylaminobiurets and Related Compounds and from
S-Benzyl 3-Acyl(thiocarbazates). J. Chem. Soc., Perkin Trans. 1 1982,
9, 2019–2021.
(63) Dornow, A.; K., B. Notiz u¨ber die Darstellung von 1.3.4-
Oxadiazolon-(5) und seinen C2-alkylierten Derivaten. Chem. Ber.
1949, 82, 121–123.
(64) Hoggarth, E. 2-Benzoyldithiocarbazinic Acid and Related Compounds.
J. Chem. Soc., Perkin Trans. 1 1952, 4811–4817.
(65) Horning, D. E.; Muchowski, J. M. Five-membered Heterocyclic
Thiones Part I. 1,3,4-Oxadiazol-2-thione. Can. J. Chem. 1972, 50,
3079–3083.
(66) Korpi, E. R.; Luddens, H. Regional gamma-aminobutyric acid
sensitivity of t- butylbicyclophosphoro[35S]thionate binding depends
on gamma-aminobutyric acidA receptor alpha subunit. Mol. Pharma-
col. 1993, 44, 87–92.
(33) Byberg, J. R.; Labouta, I. M.; Falch, E.; Hjeds, H.; Krogsgaard-Larsen,
P.; Curtis, D. R.; Gynther, B. D. Synthesis and biological activity of
a GABAA agonist which has no effect on benzodiazepine binding
and of structurally related glycine antagonists. Drug Des. DeliVery
1987, 1, 261–274.
(34) Frolund, B.; Jensen, L. S.; Storustovu, S. I.; Stensbol, T. B.; Ebert,
B.; Kehler, J.; Krogsgaard-Larsen, P.; Liljefors, T. 4-Aryl-5-(4-
piperidyl)-3-isoxazolol GABAA antagonists: synthesis, pharmacology,
and structure-activity relationships. J. Med. Chem. 2007, 50, 1988–
1992.
(35) Krehan, D.; Storustovu, S. I.; Liljefors, T.; Ebert, B.; Nielsen, B.;
Krogsgaard-Larsen, P.; Frolund, B. Potent 4-arylalkyl-substituted
3-isothiazolol GABA(A) competitive/noncompetitive antagonists:
synthesis and pharmacology. J. Med. Chem. 2006, 49, 1388–1396.
(36) Frolund, B.; Jensen, L. S.; Guandalini, L.; Canillo, C.; Vestergaard,
H. T.; Kristiansen, U.; Nielsen, B.; Stensbol, T. B.; Madsen, C.;
Krogsgaard-Larsen, P.; Liljefors, T. Potent 4-aryl- or 4-arylalkyl-
substituted 3-isoxazolol GABA(A) antagonists: synthesis, pharmacol-
ogy, and molecular modeling. J. Med. Chem. 2005, 48, 427–439.
(37) Frolund, B.; Tagmose, L.; Jorgensen, A. T.; Kristiansen, U.; Stensbol,
T. B.; Liljefors, T.; Krogsgaard-Larsen, P. Design and synthesis of a
new series of 4-alkylated 3-isoxazolol GABA A antagonists. Eur.
J. Med. Chem. 2003, 38, 447–449.
(38) Mortensen, M.; Frolund, B.; Jorgensen, A. T.; Liljefors, T.; Krogs-
gaard-Larsen, P.; Ebert, B. Activity of novel 4-PIOL analogues at
human alpha 1 beta 2 gamma 2S GABA(A) receptors-correlation
with hydrophobicity. Eur. J. Pharmacol. 2002, 451, 125–132.
(39) Frolund, B.; Jorgensen, A. T.; Tagmose, L.; Stensbol, T. B.; Vester-
gaard, H. T.; Engblom, C.; Kristiansen, U.; Sanchez, C.; Krogsgaard-
Larsen, P.; Liljefors, T. Novel class of potent 4-arylalkyl substituted
3-isoxazolol GABA(A) antagonists: synthesis, pharmacology, and
molecular modeling. J. Med. Chem. 2002, 45, 2454–2468.
(40) Frolund, B.; Kristiansen, U.; Brehm, L.; Hansen, A. B.; Krogsgaard-
Larsen, P.; Falch, E. Partial GABAA receptor agonists. Synthesis and
in vitro pharmacology of a series of nonannulated analogs of 4,5,6,7-
tetrahydroisoxazolo[5,4-c]pyridin-3-ol. J. Med. Chem. 1995, 38, 3287–
3296.
(41) Akabas, M. H.; Stauffer, D. A.; Xu, M.; Karlin, A. Acetylcholine
receptor channel structure probed in cysteine-substitution mutants.
Science 1992, 258, 307–310.
(42) Sigel, E.; Baur, R.; Kellenberger, S.; Malherbe, P. Point mutations
affecting antagonist affinity and agonist dependent gating of GABAA
receptor channels. EMBO J. 1992, 11, 2017–2023.